Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase

Rhea-AI Summary

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI) announces that David A. Hollander, M.D., M.B.A., presented on AR-15512, its dry eye product candidate, at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase. The presentation included details on the Phase 2a study and the role of TRPM8 as a target for dry eye treatment. Aerie focuses on developing first-in-class therapies for open-angle glaucoma and other ocular diseases, with products like Rhopressa and Rocklatan already launched in the U.S.

Positive

• Presentation on AR-15512 highlights potential advancements in dry eye treatment.
• Aerie continues to develop first-in-class therapies for ocular diseases.

Negative

• None.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that David A. Hollander, M.D., M.B.A., Chief Research & Development Officer presented an overview on AR-15512, Aerie’s dry eye product candidate, at the Ophthalmology Innovation Summit Dry Eye Innovation Showcase. The slide presentation includes additional details on the Phase 2a study and the role of TRPM8 as a target for the treatment of dry eye.

The slide presentation from today’s event is available now and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210311005083/en/

FAQ

What was presented by Aerie Pharmaceuticals at the Ophthalmology Innovation Summit?

David A. Hollander, M.D., M.B.A., presented an overview of AR-15512, a dry eye product candidate, detailing the Phase 2a study and TRPM8's role in treatment.

What is Aerie's focus in ophthalmology?

Aerie Pharmaceuticals focuses on the discovery and development of first-in-class therapies for open-angle glaucoma, ocular surface diseases, and retinal diseases.

What existing products has Aerie launched?

Aerie has launched Rhopressa and Rocklatan in the U.S. for the reduction of intraocular pressure in patients with open-angle glaucoma.

Where can I find more information about Aerie's presentations?

More information about Aerie's presentations is available on their official website at http://investors.aeriepharma.com.